We targeted this specific signaling response with dasatinib, a dual Src/Abl inhibitor used for treatment of chronic myeloid leukemia [103,104] For the first time, we have found that dasatinib treatment not only attenuated microgliosis, TNFα levels, and active Src levels in the brains of APP/PS1 mice but also improved cognitive performance. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.